Highlights Heron Therapeutics, Inc.

Equities

HRTX

US4277461020

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
3.69 ^USD	+2.50%		-4.40%	+117.06%

May. 29	Heron Therapeutics Submits Prior Approval Supplement to the FDA for Zynrelef Vial Access Needle	MT
May. 29	Heron Therapeutics, Inc. Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Heron Therapeutics, Inc. Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")	May. 29	CI
Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	May. 07	CI
Heron Therapeutics Shares Soar After Q4 Results Beat	Mar. 13	MT
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q4 Revenue $34.2M, vs. Street Est of $31.2M	Mar. 12	MT
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024	Mar. 12	CI
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef	Jan. 24	DJ
Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures	Jan. 23	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Boeing 737 Max 9 Grounding	Jan. 08	MT
Heron Therapeutics Unveils Deal to Expand Sales Network for Postoperative Pain Control Anesthetic; Shares Rise Premarket	Jan. 08	MT
Heron Therapeutics, Inc. Enters into Five-Year Distributor Partnership with Crosslink Life Sciences, LLC to Expand the Sales Network Supporting ZYNRELEF	Jan. 07	CI
Earnings Flash (HRTX) HERON THERAPEUTICS Posts Q3 Revenue $31.4M, vs. Street Est of $31.8M	Nov. 14	MT
Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024	Nov. 14	CI
Heron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Heron Therapeutics, Inc. Reiterates Net Product Sales Guidance for the Full Year 2023	23-08-14	CI
Heron Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Heron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Heron Therapeutics Q4 Loss Narrows, Sales Jump; Shares Climb After Hours	23-03-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Heron Therapeutics, Inc.

Equities

HRTX

US4277461020

Highlights

Filters